TMCI Valuation

Treace Medical Concepts Inc

Add to Watchlist

Advanced Chart

7.040

+0.15(2.177%)1D

Overview
Forecast
Valuation
Earnings

TMCI Relative Valuation

TMCI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMCI is overvalued; if below, it's undervalued.

Historical Valuation

Treace Medical Concepts Inc (TMCI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.85 is considered Undervalued compared with the five-year average of -33.37. The fair price of Treace Medical Concepts Inc (TMCI) is between 8.15 to 32.51 according to relative valuation methord. Compared to the current price of 7.04 USD , Treace Medical Concepts Inc is Undervalued By 13.59%.

Relative Value

Fair Zone

8.15-32.51

Current Price：7.04

13.59%

Undervalued

-8.99

Trailing

Forward

82.95

EV/EBITDA

Treace Medical Concepts Inc. (TMCI) has a current EV/EBITDA of 82.95. The 5-year average EV/EBITDA is 38.61. The thresholds are as follows: Strongly Undervalued below -986.43, Undervalued between -986.43 and -473.91, Fairly Valued between 551.12 and -473.91, Overvalued between 551.12 and 1063.64, and Strongly Overvalued above 1063.64. The current Forward EV/EBITDA of 82.95 falls within the Historic Trend Line -Fairly Valued range.

-9.48

EV/EBIT

Treace Medical Concepts Inc. (TMCI) has a current EV/EBIT of -9.48. The 5-year average EV/EBIT is -42.32. The thresholds are as follows: Strongly Undervalued below -151.38, Undervalued between -151.38 and -96.85, Fairly Valued between 12.21 and -96.85, Overvalued between 12.21 and 66.74, and Strongly Overvalued above 66.74. The current Forward EV/EBIT of -9.48 falls within the Historic Trend Line -Fairly Valued range.

1.85

Treace Medical Concepts Inc. (TMCI) has a current PS of 1.85. The 5-year average PS is 6.06. The thresholds are as follows: Strongly Undervalued below -1.95, Undervalued between -1.95 and 2.05, Fairly Valued between 10.07 and 2.05, Overvalued between 10.07 and 14.08, and Strongly Overvalued above 14.08. The current Forward PS of 1.85 falls within the Undervalued range.

-43.53

P/OCF

Treace Medical Concepts Inc. (TMCI) has a current P/OCF of -43.53. The 5-year average P/OCF is -44.22. The thresholds are as follows: Strongly Undervalued below -94.47, Undervalued between -94.47 and -69.34, Fairly Valued between -19.09 and -69.34, Overvalued between -19.09 and 6.03, and Strongly Overvalued above 6.03. The current Forward P/OCF of -43.53 falls within the Historic Trend Line -Fairly Valued range.

-27.20

P/FCF

Treace Medical Concepts Inc. (TMCI) has a current P/FCF of -27.20. The 5-year average P/FCF is -35.78. The thresholds are as follows: Strongly Undervalued below -81.37, Undervalued between -81.37 and -58.58, Fairly Valued between -12.99 and -58.58, Overvalued between -12.99 and 9.80, and Strongly Overvalued above 9.80. The current Forward P/FCF of -27.20 falls within the Historic Trend Line -Fairly Valued range.

Treace Medical Concepts Inc (TMCI) has a current Price-to-Book (P/B) ratio of 4.45. Compared to its 3-year average P/B ratio of 8.45 , the current P/B ratio is approximately -47.31% higher. Relative to its 5-year average P/B ratio of 2.87, the current P/B ratio is about 55.11% higher. Treace Medical Concepts Inc (TMCI) has a Forward Free Cash Flow (FCF) yield of approximately -6.70%. Compared to its 3-year average FCF yield of -6.91%, the current FCF yield is approximately -3.11% lower. Relative to its 5-year average FCF yield of -5.29% , the current FCF yield is about 26.57% lower.

4.45

P/B

Median3y

8.45

Median5y

2.87

-6.70

FCF Yield

Median3y

-6.91

Median5y

-5.29

Competitors Valuation Multiple

The average P/S ratio for TMCI's competitors is 2.18, providing a benchmark for relative valuation. Treace Medical Concepts Inc Corp (TMCI) exhibits a P/S ratio of 1.85, which is -15.12% above the industry average. Given its robust revenue growth of 6.60%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TMCI.O

Treace Medical Concepts Inc

Standard BioTools Inc

Pacific Biosciences of California Inc

2.31

10.42%

399.49M

Performance Decomposition

Market capitalization of TMCI increased by 14.10% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -6.69 to -8.74.

The secondary factor is the Revenue Growth, contributed 6.60%to the performance.

Overall, the performance of TMCI in the past 1 year is driven by P/E Change. Which is more unsustainable.

6.60%

44.46M → 47.39M

Revenue Growth

-23.04%

-47.70 → -36.71

Margin Expansion

30.54%

-6.69 → -8.74

P/E Change

14.10%